13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

      American journal of respiratory and critical care medicine

      Analysis of Variance, Animals, Antitubercular Agents, pharmacology, Aza Compounds, Biological Availability, Culture Media, Disease Models, Animal, Drug Therapy, Combination, Female, Fluoroquinolones, Mice, Mice, Inbred BALB C, Microbial Sensitivity Tests, Mycobacterium tuberculosis, drug effects, growth & development, Probability, Quinolines, Sensitivity and Specificity, Time Factors, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

          Related collections

          Author and article information

          Journal
          14578218
          10.1164/rccm.200310-1380OC

          Comments

          Comment on this article